Real World Strategies for LDL-Mediated Cardioprotection in High Risk and Statin Intolerant Patients Requiring LDL Reduction: Which Agents? In What Sequence? In Which Patient Subsets? A Roadmap to Clinical Success - Michael H. Davidson, MD, FACC, FACP, FNLA